TLP
NTLA icon

Tri Locum Partners’s Intellia Therapeutics NTLA Stock Holding History

Tri Locum Partners’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-56,402
Closed -$3.07M – 67
2020
Q4 		$3.07M Buy
+56,402
New +$2.05M 1.11% 25

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Chevy Chase Trust
Chevy Chase Trust Bethesda, Maryland $34.7B AUM 29.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Tri Locum Partners's NTLA Position: Q1 2021 in Review

Tri Locum Partners sold out of Intellia Therapeutics (NTLA) in Q1 2021, closing a stake of 56,402 shares — an estimated $3.07M sold.

Tri Locum Partners first reported a position in NTLA in Q4 2020 and held it in 1 quarter. The position peaked at $3.07M in Q4 2020. 260 funds tracked by Wall St. Rank hold NTLA as of Q1 2021.

  • Tri Locum Partners reported no remaining Intellia Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Tri Locum Partners sold 56,402 Intellia Therapeutics shares in Q1 2021, an estimated $3.07M.
  • Tri Locum Partners first reported a position in Intellia Therapeutics in Q4 2020 and held it in 1 quarter.
  • Tri Locum Partners's Intellia Therapeutics position peaked at $3.07M in Q4 2020.
  • 260 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2021.

Based on Tri Locum Partners's 13F filing for Q1 2021, filed 17 May 2021.